Reuters logo
BRIEF-Intersect ENT says FDA approves steroid releasing implant Propel Contour
February 24, 2017 / 1:20 PM / 9 months ago

BRIEF-Intersect ENT says FDA approves steroid releasing implant Propel Contour

Feb 24 (Reuters) - Intersect Ent Inc

* Intersect ENT announces FDA approval of newest steroid releasing implant, Propel Contour, for use in treating the frontal and maxillary sinuses

* Intersect ENT Inc - expects to launch propel contour broadly in Q2 of 2017 and maintains its previously stated 2017 revenue guidance of $87-$89 million

* FY2017 revenue view $88.0 million -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below